Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Dexcom, Inc. securities between July 26, 2024 and September 17, 2025.
“We know from data that primary care, which sees over 90% of patients with type 2 diabetes, that there’s not much uptake or ...
Many people are wearing glucose monitors despite them not having diabetes as an approach to weight loss and to improve ...
The complaint alleges that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) DexCom had made material design changes to its G6 and G7 ...
Continuous glucose monitoring can identify unrecognized hyperglycemia and hypoglycemia in dialysis patients, challenging reliance on A1c for diabetes management.
In a significant step towards modernizing diabetes management in Sri Lanka, Tranz Pharma Holdings has officially introduced ...
Dexcom (($DXCM)) has held its Q3 earnings call. Read on for the main highlights of the call. DexCom’s recent earnings call conveyed a generally ...
The continuous glucose monitoring powerhouse saw its share price drop a frightening 17% in the first two hours of trading on Oct. 31, pushing it down by one-third from its peak of $89.53 in late July.
Aptiva Medical will use its recent acquisition of VeraMed Health and a laser focus on continuous glucose monitors (CGMs) to position itself as a leader in the market, says ...
Amid some scrutiny over its latest-generation G7 CGM, Dexcom officials addressed claims on the company's latest earnings call ...
Eliud Kipchoge reveals how his nutrition, hydration, and discipline power his reign as the world’s greatest marathon runner.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results